

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number  
**WO 01/32683 A1**

- (51) International Patent Classification<sup>7</sup>: C07J 73/00
- (21) International Application Number: PCT/CA99/01017
- (22) International Filing Date:  
1 November 1999 (01.11.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (for all designated States except US): TOR-CAN CHEMICAL LTD. [CA/CA]; 110 Industrial Parkway North, Aurora, Ontario L4G 3H4 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): SLEMON, Clarke [CA/CA]; 152 Upper Canada Drive, Willowdale, Ontario M2P 1S8 (CA).
- (74) Agent: HIRONS, Robert, G.; Ridout & Maybee, 150 Metcalfe Street, 18th Floor, Ottawa, Ontario K2P 1P1 (CA).
- (81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/32683 A1


(54) Title: PRODUCTION OF POLYMORPHIC FORMS I AND II OF FINASTERIDE BY COMPLEXATION WITH GROUP I OR II METAL SALTS

(57) Abstract: Polymorphic Form (I) finasteride is prepared by first forming a substantially insoluble complex of finasteride and a Group (I) or Group (II) metal salt, such as lithium bromide, and then dissociating the complex by dissolving away the salt component with water, so as to obtain substantially pure Form (I) polymorphic crystalline finasteride.

PRODUCTION OF POLYMORPHIC FORMS I AND II OF FINASTERIDE BY COMPLEXATION WITH GROUP I  
OR II METAL SALTS

5 This invention relates to finasteride, a 4-aza-steroid compound which exhibits pharmaceutical activity as an inhibitor of the enzyme testosterone 5- $\alpha$ -reductase, and is useful in the treatment of prostate cancer. More specifically, it relates to processes for preparing finasteride in a specific, polymorphic form.

10 Finasteride is, chemically, (5 $\alpha$ , 17 $\beta$ )-N-(1,1-dimethylethyl)-3-oxo-4-aza-androst-1-ene-17-carboxamide, of chemical structural formula:



25 It is reported to be active in inhibiting the activity of the enzyme testosterone-5- $\alpha$ -reductase, which causes reduction of testosterone in the body to dihydrotestosterone, DHT, implicated in the enlargement of the prostate and consequent development of malignant conditions namely prostate cancer. Accordingly, finasteride is prescribed for alleviation of prostate cancer.

30 Finasteride can exist in two different polymorphic forms, Form I and Form II, which differ from one another in respect of their crystalline structure. The different polymorphic forms can be prepared by control of the

crystallization conditions. Finasteride polymorphic Form I is the usual form and is the form which is marketed as the active ingredient of the finasteride drug formulation PROSCAR®. According to Canadian Patent Application 2,103,107 Dolling et al. (equivalent to European patent application 0599376), finasteride polymorphic Form I is characterized by an X-ray powder diffraction pattern having d-spacings of 6.44, 5.69, 5.36, 4.89, 4.55, 4.31, 3.85, 3.59 and 3.14. According to the same Canadian patent, finasteride polymorphic Form II is characterized by an X-ray powder diffraction pattern having d-spacings of 14.09, 10.36, 7.92, 7.18, 6.40, 5.93, 5.66, 5.31, 4.68, 3.90, 3.60 and 3.25.

The preparation of finasteride is described and claimed in U.S. Patent 4,377,584 and further described in U.S. Patent 4,760,071. Other patents which pertain to the preparation of finasteride include Canadian patent application 2,029,859; U.S. patents 5,084,574 and 5,116,983; and Canadian patent applications 2,049,882 and 2,049,881. All these teach the conversion of a final intermediate to finasteride, which is purified and isolated as a crystalline solid. Although finasteride polymorphs are not mentioned specifically in these items of prior art, the finasteride obtained using them, as a crystalline solid, must be in one or other of the known polymorphic forms, or a mixture of both of them.

Aforementioned Canadian Patent Application 2,103,107 Dolling et al., published May 20, 1994, describes preparations of finasteride and the specific polymorphic Form I and Form II thereof. In particular, it teaches that polymorphic Form I can be prepared by crystallization from a mixture of finasteride in an organic solvent and optionally water, such that the amount of organic solvent and water in the mixture is sufficient to cause the solubility of the non-solvated form of finasteride (Form I) to be exceeded and the non-solvated form of finasteride to be less soluble than any other form of finasteride in the mixture. It also teaches that the polymorphic Form I of finasteride can be prepared by heating the polymorphic Form II of finasteride to at least 25°C in water or an organic solvent for a sufficient period of time to effect the

conversion. The same reference teaches that polymorphic Form II finasteride can be prepared by crystallization from a mixture of finasteride in an organic solvent and water, such that the amount of organic solvent and water in the mixture is sufficient to cause the solubility of the solvated form of finasteride to be exceeded and the solvated form of finasteride to be less soluble than any other form of finasteride in the mixture, followed by recovery of the solid and removal of the solvent therefrom; or by heating polymorphic Form I finasteride to at least to about 150°C for sufficient time to complete the conversion.

Purifying crude organic compounds by treating with Group I and Group II metal salt in a non-hydroxylic solvent to precipitate metal salt complexes has been described in GB 2094795, U.S. 4,452,994 and U.S. 4,529,811. The hypothesis has been offered that the crystal lattice energy between the very small ion radius of the Group I or Group II metal cation and the much larger ion radius of the chosen anion tends to promote the inclusion of organic substances in the lattice when such substances are capable of helping the solvation of the small cation; but, the actual formation of such complexes cannot be reliably predicted for complex molecules and so must be demonstrated by experiment.

It is an object of the present invention to provide a novel process for preparing finasteride in its pharmaceutically desirable, polymorphic Form I.

It is a further object of the invention to provide novel intermediates useful in preparation of polymorphic Form I finasteride and in other aspects of finasteride preparation.

According to one aspect of the present invention, there is provided a process of preparing polymorphic Form I finasteride, which comprises preparing a finasteride - Group I or Group II metal salt complex, in the presence of a non-hydroxylic solvent, dissociating the complex by addition

of acidified water thereto, and recovering the crystalline Form I finasteride so formed.

5 According to a second aspect of the present invention, there are provided chemical complexes of finasteride and the salt of a Group I or Group II metal, said complexes being dissociable upon addition of acidified water thereto, to yield water-insoluble polymorphic Form I finasteride.

10 According to a further aspect of the invention, there is provided a process for preparing chemical complexes of finasteride and a Group I or Group II metal salt, which comprises dissolving crude finasteride in a non-hydroxylic, chemically inert, organic solvent, and adding to the solution so formed a salt of a Group I or Group II metal.

15 The finasteride-metal salt complexes formed in the process of the present invention have been found, by X-ray powder diffraction, to be nearly amorphous solids. Neither the spectral lines of Form I or Form II of finasteride are present in these amorphous solids. When these complexes are dissociated according to the process of the invention, by addition of acidified water thereto,  
20 the metal salt is dissolved and the solid which is obtained upon filtration, surprisingly and unpredictably, turns out to be finasteride Form I. The precursor complexes, and any finasteride solvates initially present, as impure substances, do not of course exhibit polymorphic crystalline forms.

25 Another aspect of the invention is a method of isolating finasteride in substantially pure, polymorphic Form I, from a solution thereof in an organic non-hydroxylic solvent, which comprises adding to said solution a salt of a Group I or Group II metal to form a sparingly soluble complex thereof with finasteride, separating the finasteride complex by filtration, and adding acidified  
30 water thereto to break the complex and form substantially pure, isolatable polymorphic Form I finasteride.

5 Addition of acidified water e.g. water containing about 10% v/v acetic acid, to the amorphous solid complex removes the metal salt by dissolution into the aqueous solution, and catalyses the transformation of the finasteride component, which never dissolves, into polymorphic Form I finasteride in substantially pure condition, which can be filtered, washed and dried.

10 The Group I or Group II metal salts preferably used in the present invention are lithium salts and calcium salts, and most preferably lithium salts with relatively large anions, for example bromide, iodide, tetrafluoroborate, perchlorate, hexafluorophosphate and the like. Especially preferred is lithium bromide.

15 In the preparation of the finasteride-metal complexes according to the invention, finasteride in any of its polymorphic forms, as mixtures of polymorphic forms, or as a solvate with an organic solvent, or in impure form, in solution in a non-hydroxylic, non-reactive organic solvent, is dissolved in a non-hydroxylic organic solvent which does not contain complexable functional groups which will interact with the finasteride. In a particular preferred  
20 embodiment, the finasteride solution is that resulting from the work-up of the reaction mixture from the chemical synthesis of finasteride, for example by the method of reacting (5 $\alpha$ , 17 $\beta$ )-N-(1,1-dimethylethyl)-3-oxo-4-aza-androstan-17-carboxamide with dichlorodicyanoquinone and bistrimethylsilyltrifluoroacetamide in solution in an non-hydroxylic inert organic  
25 solvent. The metal salt is added to this solution, and sparingly soluble finasteride-metal salt complex precipitates. This finasteride-metal salt complex can optionally be dried, with or without the application of heat. Suitable solvents include hexanes and other aliphatic and cycloaliphatic hydrocarbons, aromatic hydrocarbons such as benzene, toluene, xylenes, halogenated aliphatic  
30 hydrocarbons such as methylene chloride and other chlorinated hydrocarbons, ethers such as diethylether, diisopropyl ether and t-butylmethyl ether, and

ketones such as methyl isobutyl ketone, and mixtures of two or more mutually compatible such solvents. The quantity of solvent is not critical.

The finasteride-metal salt complexes may be prepared at any suitable temperature at which the chosen solvent remains liquid. The chosen temperature is not critical. Room temperatures are suitable and convenient. Similarly the stoichiometry of the finasteride and the metal salt is not critical, although operating at close to stoichiometric ratios is economical and avoids waste of reagents.

The complex formation benefits from the presence in the organic solvent solution of a small, catalytic quantity of water or lower ( $C_1-C_6$ ) alkanol. This has the effect of increasing the rate of formation of the complex. The catalyst quantity should be chosen so as to be adequate to exert its catalytic, accelerating effect, but not sufficient to compete significantly for the metal salt or to increase significantly the low solubility of the complex. Amounts up to about 1% of water or lower alkanol are suitable.

The invention is illustrated in the following specific examples.

#### Example 1- Preparation of Finasteride-Lithium Bromide Complex

Into a 100 ml r.b. flask equipped with a magnetic stirrer and a nitrogen inert atmosphere was weighted 3.71 gm of finasteride. Methylene chloride (20 ml) was added and the slurry stirred to dissolve the substrate. To the clear light yellow solution was added 0.87 g of anhydrous lithium bromide. The solid was washed down into the reaction with 5 ml of methylene chloride. The slurry was stirred. Within one minute add 1 drop of n-propanol from a disposable pipette. The slurry was stirred overnight with exclusion of moisture under an inert nitrogen atmosphere. The slurry is filtered on a Buchner funnel and the flask and solid washed with 10 ml of methylene chloride. After drying

the solid at 50°C in vacuum the solid complex weighs 4.17 g. The methylene chloride solution contains .35 g of nonvolatile residue.

Example 2 - Preparation of Finasteride Form I

5

In a 25 ml r.b. flask equipped with a magnetic stirrer and a static nitrogen purge was placed 0.53 g of finasteride-lithium bromide complex. To this was added 10 ml of 9:1 v/v water/acetic acid and the slurry was stirred for two hours at 50°C. The slurry was cooled to 20-25°C and filtered. The solid on the filter was washed with water and dried in vacuum at 40-45°C. The solid weighed 0.37 g.

10

Three different samples of finasteride prepared in three separate experiments according to this Example 2 were analyzed by x-ray powder diffraction, and the single Figure of accompanying drawings shows these three x-ray powder diffraction patterns. They are identical to one another, and identify the products as finasteride Form I. Further confirmation of the identity of the product as finasteride Form I was obtained by differential scanning calorimetry.

15

20



## I CLAIM:

- 5                   1. A process of preparing polymorphic Form I finasteride, which comprises preparing a finasteride - Group I or Group II metal salt complex, in the presence of a non-hydroxylic solvent, dissociating the complex by addition of acidified water thereto, and recovering the crystalline Form I finasteride as formed.
- 10                   2. The process of claim 1 wherein the metal salt of the complex is a lithium salt with a relatively large anion.
3. The process of claim 2 wherein the lithium salt is lithium bromide.
- 15                   4. The process of claim 1, claim 2 or claim 3 wherein the acidified water is a water-acetic acid mixture.
- 20                   5. The process of claim 1 wherein the non-hydroxylic solvent is an aliphatic hydrocarbon, a cycloaliphatic hydrocarbon, a halogenated aliphatic hydrocarbon, an aromatic hydrocarbon, an ether, a ketone or a mixture of two or more compatible such solvents.
6. The process of claim 5 wherein the solvent is methylene chloride.
- 25                   7. A chemical complex of finasteride and a Group I or Group II metal salt, said complex being dissociable upon addition of acidified water thereto, to yield water-insoluble polymorphic Form I finasteride.
- 30                   8. The complex of claim 7 wherein the metal salt is a lithium salt with a relatively large anion.

9. The complex of claim 8 wherein the metal salt is lithium bromide.

5 10. A process for preparing a chemical complex of finasteride and a Group I or Group II metal salt, which comprises dissolving crude finasteride in a non-hydroxylic, chemically inert, organic solvent, and adding to the solution so formed a salt of a Group I or Group II metal.

10 11. The process of claim 10 wherein the salt is a lithium salt with a relatively large anion.

12. The process of claim 11 wherein the salt is lithium bromide.


15 13. The process of claim 10, claim 11 or claim 12 catalysed by a catalytic amount of water or lower ( $C_1$ - $C_6$ ) alkanol in the reaction medium.

20 14. A method of isolating finasteride in substantially pure, polymorphic Form I, from a solution thereof in an organic non-hydroxylic solvent, which comprises adding to said solution a salt of a Group I or Group II metal to form a sparingly soluble complex thereof with finasteride, separating the finasteride complex by filtration, and adding acidified water thereto to break the complex and form substantially pure, isolatable polymorphic Form I finasteride.

25 15. The method of claim 14 wherein the salt is a lithium salt with a relatively large anion.

16. The method of claim 15 wherein the salt is lithium bromide.

30 17. The method of claim 14, claim 15 or claim 16 wherein the insoluble complex is formed in the presence of a catalytic amount of water or lower ( $C_1$ - $C_6$ ) alkanol.



FIGURE

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 99/01017

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07J73/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 823 436 A (MERCK & CO INC) 11 February 1998 (1998-02-11) page 5, line 17 -page 6, line 36; claims 1-13; examples 3,4	1-17
A	WAWRZYCKA, IRENA ET AL: "Structural characterization of polymorphs and molecular complexes of finasteride" J. MOL. STRUCT. (1999), 474, 157-166 , XP002139610 the whole document	1-17

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

7 June 2000

Date of mailing of the international search report

04/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

# INTERNATIONAL SEARCH REPORT

Inter national Application No

PCT/CA 99/01017

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J A MCCAULEY ET AL: "Detection and Characterization of Polymorphism in the Pharmaceutical Industry" AMERICAN INSTITUTE OF CHEMICAL ENGINEERS. ANNUAL MEETING, XX, XX, no. 87, 1 January 1991 (1991-01-01), pages 58-63, XP002078540 page 60, column 2, paragraph 1 -page 61, column 1, paragraph 1; figures 3,4	1-17
A	GB 2 094 795 A (G. D. SEARLE & CO) 22 September 1982 (1982-09-22) examples 3-8	1-17
E	GB 2 338 234 A (TORCAN CHEMICAL LTD) 15 December 1999 (1999-12-15) the whole document	1-17

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/01017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0823436 A	11-02-1998	US 5468860 A	21-11-1995
		EP 0655458 A	31-05-1995
		GR 95300043 T	31-07-1995
		GR 3029554 T	30-06-1999
		AT 164850 T	15-04-1998
		AT 177112 T	15-03-1999
		AU 658774 B	27-04-1995
		AU 5078793 A	16-06-1994
		BG 62362 B	30-09-1999
		BG 99637 A	30-04-1996
		BG 103170 A	30-09-1999
		CA 2103107 A	20-05-1994
		CN 1090583 A	10-08-1994
		CZ 9501268 A	13-12-1995
		DE 69317856 D	14-05-1998
		DE 69317856 T	05-11-1998
		DE 69323754 D	08-04-1999
		DE 69323754 T	07-10-1999
		DE 599376 T	08-12-1994
		DE 655458 T	30-11-1995
		DK 599376 T	11-05-1998
		EP 0599376 A	01-06-1994
		ES 2052476 T	16-07-1994
		ES 2072848 T	01-08-1995
		FI 952422 A	18-05-1995
		GR 94300045 T	29-07-1994
		GR 3026577 T	31-07-1998
		HR 931410 A	30-06-1996
		HU 66973 A, B	30-01-1995
		HU 9400041 A	28-12-1994
		JP 2742409 B	22-04-1998
		JP 9235294 A	09-09-1997
		JP 6199889 A	19-07-1994
		JP 7110875 B	29-11-1995
		LV 12212 A	20-01-1999
		LV 12212 B	20-03-1999
		MX 9307222 A	29-07-1994
		NO 951986 A	19-05-1995
		NO 990468 A	19-05-1995
		NO 992580 A	19-05-1995
		PL 309050 A	18-09-1995
		RO 115164 A	30-11-1999
		RO 115165 A	30-11-1999
		RU 2120445 C	20-10-1998
		SI 9300603 A	30-06-1994
		SK 65995 A	11-10-1995
		WO 9411387 A	26-05-1994
		US 5652365 A	29-07-1997
		US 5886184 A	23-03-1999
		ZA 9308620 A	04-08-1994
GB 2094795 A	22-09-1982	US 4452994 A	05-06-1984
		DE 3207470 A	07-10-1982
		FR 2509288 A	14-01-1983
		GB 2144747 A, B	13-03-1985
		JP 1709964 C	11-11-1992
		JP 3079329 B	18-12-1991
		JP 57158726 A	30-09-1982

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/CA 99/01017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2094795 A		JP 2885386 B JP 4210985 A US 4529811 A	19-04-1999 03-08-1992 16-07-1985
GB 2338234 A	15-12-1999	NONE	

**THIS PAGE BLANK (USPTO)**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**